Treatment of children with newly diagnosed brain stem gliomas with intravenous recombinant β-interferon and hyperfractionated radiation therapy: A childrens cancer group phase I/II study

Cancer

Volumn 77, Issue 10, 1996, Pages 2150-2156

  Packer, Roger J ^a,h   Prados, Michael ^b   Phillips, Peter ^c   Nicholson, H Stacy ^a   Boyett, James M ^d   Goldwein, Joel ^c   Rorke, Lucy B ^c   Needle, Michael N ^c   Sutton, Leslie ^c   Zimmerman, Robert A ^c   Fitz, Charles R ^e   Vezina, L Gilbert ^a   Etcubanas, Erlinda ^f   Wallenberg, Joy C ^f   Reaman, Gregory ^a   Wara, William ^g  

^a GEORGE WASHINGTON UNIVERSITY SCHOOL OF MEDICINE AND HEALTH SCIENCES   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

^d ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^e CHILDREN S HOSPITAL OF PITTSBURGH   (United States)

^f Berlex Laboratories ^*  (United States)

^g UNIVERSITY OF CALIFORNIA   (United States)

^h CHILDREN S ONCOLOGY GROUP   (United States)

Author keywords

brain stem gliomas; brain tumor; hyperfractionated radiotherapy; immunotherapy; interferon; radiotherapy

Indexed keywords

RECOMBINANT BETA INTERFERON;

ADOLESCENT; ARTICLE; BLOOD TOXICITY; BRAIN STEM TUMOR; CANCER RADIOTHERAPY; CHILD; CLINICAL ARTICLE; CLINICAL TRIAL; DOSE RESPONSE; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LIVER TOXICITY; MALE; MULTICENTER STUDY; NEUROTOXICITY; PRIORITY JOURNAL; RADIATION DOSE FRACTIONATION;

ADOLESCENT; BRAIN NEOPLASMS; BRAIN STEM; CHILD; CHILD, PRESCHOOL; COMBINED MODALITY THERAPY; FEMALE; GLIOMA; HUMANS; INTERFERON-BETA; MALE; NAUSEA; SURVIVAL RATE; TREATMENT OUTCOME; VOMITING;

EID: 15844429511     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0142(19960515)77:10<2150::AID-CNCR28>3.0.CO;2-T     Document Type: Article

References (19)

1. Packer RJ, Nicholson HS, Johnson DS, Vezina LG. Dilemmas in the management of childhood brain tumors: brain stem gliomas. Pediatr Neurosurg 1991;17:37-43.
2. Barkovich AJ, Krischer J, Kun L, Packer RJ, Zimmerman RA, Freeman CR, et al. The characteristics of brainstem gliomas: correlation with survival statistics in a three-center study. Pediatr Neurosci 1991;16:73-83.
3. Packer RJ, Boyett JM, Zimmerman RA, Albright AL, Kaplan AM, Rorke LB, et al. Outcome of children with brain stem gliomas after treatment with 7800 cGy of hyperfractionated radiotherapy: a Childrens Cancer Group Phase I/II trial, Cancer 1994;74:1827-34.
4. Packer RJ, Allen JC, Goldwein JL, Newall J, Zimmerman RA, Priest J, et al. Hyperfractionated radiotherapy for children with brainstem gliomas: a pilot study using 7,200 cGy. Ann Neurol 1990;27:167-73.
5. Freeman CR, Krischer J, Sanford RA, Cohen ME, Burger PC, Kun L, et al. Hyperfractionated radiation therapy in brain stem tumors: results of treatment at the 7020 cGy dose level. Pediatric Oncology Group study #8495. Cancer 1991;68:474-81.
6. Shreive DC, Wara WM, Edwards MSB, Sneed PK, Prados MO, Cogen RH, et al. Hyperfractionated radiation therapy for gliomas of the brainstem in children and adults. Int J Radiat Oncol Biol Phys 1992;24:599-610.
7. Packer RJ, Boyett JM, Zimmerman RA, Rorke LB, Allen AM, Albright AL, et al. Hyperfractionated radiotherapy (72 Gy) for children with brain stem gliomas: a Childrens Cancer Group Phase I/II trial. Cancer 1993;72:1414-21.
8. Yung WKA, Prados M, Levin VA, Fetell MR, Bennett J, Mahaley MS, et al. Intravenous recombinant interferon beta in patients with recurrent malignant gliomas: a phase I/II study. J Clin Oncol 1991;9:1945-9.
9. Allen J, Packer R, Bleyer A, Zeltzer P, Prados M, Nirenberg A. Recombinant beta-interferon (Betaseron): a phase I-II trial in children with recurrent brain tumors. J Clin Oncol 1991;9:783-8.
10. Gould MN, Kakria RC, Olson S, Borden EC. Radiosensitization of human bronchogenic carcinoma cells by interferon beta. J Interferon Res 1984;4:124-8.
11. 2-M phase of the cell cycle. Cancer Res 1984;47:4338-41.
12. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Star Assoc 1958;53:457-81.
13. Peto R, Pike MC, Armitage P, Breslow NE, Cox DR, Howard SV, et al. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. I. Introduction and Design. Br J Cancer 1976;34:1-11.
14. Mahaley MS, Urso MB, Whaley RA, Blue M, Williams TE, Guaspari A, et al. Immunobiology of primary intracranial tumors: Part 10: therapeutic efficacy of interferon in the treatment of recurrent gliomas. J Neurosurg 1985;63:719-25.
15. Mahaley MS Jr, Gillepsie GY. Immunologic consideration of patients with brain tumors. In: Walker MD, editor. Oncology of the nervous system. Boston: Martinus Nikhoff Publishers, 1983:151-65.
16. Nagai M, Arai T. Interferon therapy for malignant brain tumors: present and future. No Shinkei Geka 1982;10:463-76.
17. Nagai M, Arai T. Clinical effect of interferon in malignant brain tumors. Neurosurg Rev 1984;7:55-64.
18. Edwards MSB, Wara WM, Urtasun RC, Prados M, Levin VA, Fulton D, et al. Hyperfractionated radiation therapy for brainstem gliomas: a Phase I-II trial. J Neurosurg 1989;70: 691-700.
19. Packer RJ, Kramer ED, Ryan J. Biologic and immune modulating agents in the treatment of childhood brain tumors. Neurol Clin 1992;9:405-22.